Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Androgen Deprivation Therapy for Prostate Cancer: Involving Primary Care

December 7th 2016

Shared Care in Prostate Cancer

December 7th 2016

Shared Decision Making for Prostate Cancer

December 7th 2016

Who to Screen: Finding the High-Risk Prostate Cancer Patient

December 7th 2016

DNA Repair Defects Emerge as a New Category for Anticancer Therapies

December 2nd 2016

A coordinated network of signaling pathways works to protect the cell from the toxic effects of DNA damage.

Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

December 2nd 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate Cancer

December 2nd 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.

Future of Genetic Testing and Treatment in Prostate Cancer

December 1st 2016

PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer

December 1st 2016

Identifying Bone Progression in Metastatic Prostate Cancer and Treatment Options

December 1st 2016

Immunotherapy and the Abscopal Effect in Treating Metastatic Prostate Cancer

December 1st 2016

Radium-223 Alone and with Other Agents for Prostate Cancer

December 1st 2016

FDA-approved Indications for Treatment Versus Use in Current Clinical Trials

December 1st 2016

Clinical Trials in Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

Challenges in Treating Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

Decisions on Choosing LHRH Agonists for Treating Prostate Cancer

December 1st 2016

Use of LHRH Agonists Versus Antagonists in Prostate Cancer

December 1st 2016

Multidisciplinary Approach and Role of PSA and Testosterone Monitoring in Prostate Cancer

December 1st 2016

Intermittent versus Continuous Androgen-Deprivation Therapy in Prostate Cancer

December 1st 2016

Advanced Imaging Techniques for Prostate Cancer

December 1st 2016